Company Overview and News
2017-10-16 accesswire
LOS ANGELES, CA / ACCESSWIRE / October 16, 2017 / StockNewsNow.com, The Official MicroCap News Source™, today published SNNLive Video Interview with Jeff Williams, Managing Director of MacPhersons Resources Ltd. (ASX: MRP), a Western Australian resource company with its focus on the advanced gold project at Boorara and the nearby Nimbus silver/zinc project is now under review for further metallurgical test work, according to the company's website (see here: www.
Upvote
Downvote
2017-10-02 proactiveinvestors.com.au
Macphersons Resources Ltd (ASX:MRP) has commenced infill drilling targeting an upgraded resource for its Boorara gold project, located in the Goldfields region of Western Australia.
Upvote
Downvote
2017-09-16 proactiveinvestors.com.au
MacPhersons Resources Ltd (ASX:MRP) has raised circa $2.93 million via a share placement to accelerate drilling at its Boorara gold project 10 kilometres east of Kalgoorlie.
Upvote
Downvote
2017-08-07 abc.net.au
A West Australian Indigenous leader has defended the practice of Welcome to Country ceremonies, after a mining conference in Kalgoorlie tried to cancel his address.
Upvote
Downvote
2017-08-04 proactiveinvestors.com.au
MacPhersons Resources (ASX:MRP) has revealed another positive set of drill results from the Boorara gold project, 10 kilometres east of Kalgoorlie in Western Australia.
Upvote
Downvote
2017-07-03 proactiveinvestors.com.au
MacPhersons Resources Ltd (ASX:MRP) has achieved gold recoveries of 89% to 96% from the initial test work on ore samples from the Boorara Gold Project in Western Australia.
Upvote
Downvote
2017-03-31 londonstockexchange
· Further to the announcement of 1 September 2016, the Company is pleased to advise Mr Peter Reeve and Mr Jeffrey Williams have been appointed as Non-Executive Director and Executive Director of the Company with immediate effect.
Upvote
Downvote
2017-02-27 proactiveinvestors.com.au
MacPhersons Resources (ASX:MRP) has been granted a trading halt, pending results of further drilling on the Boorara gold project, located in Western Australia.
Upvote
Downvote
2017-01-27 proactiveinvestors.com.au
This is based on a 0.4 g/t gold cut-off grade with a maximum top cut grade of 24 g/t gold.
Upvote
Downvote
2017-01-18 proactiveinvestors.com.au
The 5,488 metre air core wide spread drill program about 500 metres north of the Northern Stockwork deposit reported significant intercepts, including:
Upvote
Downvote
2016-12-15 proactiveinvestors.com.au
Great Boulder Resources (ASX:GBR) listed on the ASX in November this year after consolidating a high quality portfolio of five exploration gold projects in the world-class gold camps of the Eastern Goldfields in Western Australia.
Upvote
Downvote
2016-11-14 proactiveinvestors.com.au
The company reported a revenue of $2.58 million from the gold sale. The Boorara oxide ore was milled at the FMR Coolgardie mill, 60 kilometres from Boorara. The final costs are still being compiled. Operating costs are within budgeted costs and the operation is expected to be cashflow positive. MacPhersons extracted circa 34,000 tonnes grading an estimated 1.8 grams g/t gold from 20 metres depth in the Southern Stockwork deposit.
Upvote
Downvote
2016-08-02 proactiveinvestors.com.au
MacPhersons Resources Ltd (ASX:MRP) is a Western Australian resource company with a number of advanced gold, silver and zinc exploration projects within close proximity to Kalgoorlie and Coolgardie.
Upvote
Downvote
2016-07-31 proactiveinvestors.com.au
MacPhersons Resources Ltd (ASX:MRP) is a Western Australian resource company with a number of advanced gold, silver and zinc exploration projects within close proximity to Kalgoorlie and Coolgardie.
Upvote
Downvote
2016-07-14 abc.net.au
The consumer-led power revolution driving a rapid uptake of rooftop solar panels and lithium-ion batteries to store electricity is creating new uses for metals which have long languished in the doldrums.
Upvote
Downvote
Related Articles
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...